Aliases & Classifications for Osteonecrosis

Summaries for Osteonecrosis

MedlinePlus : 41 osteonecrosis is a disease caused by reduced blood flow to bones in the joints. in people with healthy bones, new bone is always replacing old bone. in osteonecrosis, the lack of blood causes the bone to break down faster than the body can make enough new bone. the bone starts to die and may break down. you can have osteonecrosis in one or several bones. it is most common in the upper leg. other common sites are your upper arm and your knees, shoulders and ankles. the disease can affect men and women of any age, but it usually strikes in your thirties, forties or fifties. at first, you might not have any symptoms. as the disease gets worse, you will probably have joint pain that becomes more severe. you may not be able to bend or move the affected joint very well. no one is sure what causes the disease. risk factors include long-term steroid treatment alcohol abuse joint injuries having certain diseases, including arthritis and cancer doctors use imaging tests and other tests to diagnose osteonecrosis. treatments include medicines, using crutches, limiting activities that put weight on the affected joints, electrical stimulation and surgery. nih: national institute of arthritis and musculoskeletal and skin diseases

MalaCards based summary : Osteonecrosis, also known as bone necrosis, is related to osteonecrosis of the jaw and dysbaric osteonecrosis, and has symptoms including back pain, muscle cramp and sciatica. An important gene associated with Osteonecrosis is BMP2 (Bone Morphogenetic Protein 2). The drugs Alendronate and Zoledronic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and skin.

Disease Ontology : 12 An ischemic bone disease that results_in necrosis located in bone.

Related Diseases for Osteonecrosis

Graphical network of the top 20 diseases related to Osteonecrosis:



Diseases related to Osteonecrosis

Symptoms & Phenotypes for Osteonecrosis

UMLS symptoms related to Osteonecrosis:


back pain, muscle cramp, sciatica

Drugs & Therapeutics for Osteonecrosis

Drugs for Osteonecrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4,Phase 2 121268-17-5, 66376-36-1 2088
2
Zoledronic acid Approved Phase 4,Phase 3,Phase 2 118072-93-8 68740
3
Etidronic acid Approved Phase 4 7414-83-7, 2809-21-4 3305
4
Dalteparin Approved Phase 4 9041-08-1
5
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
6
Rivaroxaban Approved Phase 4 366789-02-8
7
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
8
Pentoxifylline Approved, Investigational Phase 4,Phase 3 6493-05-6 4740
9
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-02-9 14985
10 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Diphosphonates Phase 4,Phase 3,Phase 2,Phase 1
12 glucocorticoids Phase 4,Phase 3
13 Hormone Antagonists Phase 4,Phase 3,Phase 2
14 Hormones Phase 4,Phase 3,Phase 2
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
16 Anesthetics Phase 4,Phase 3,Phase 2,Early Phase 1
17 Anticoagulants Phase 4
18 Antithrombin III Phase 4
19 Antithrombins Phase 4
20 calcium heparin Phase 4
21 Factor Xa Inhibitors Phase 4
22 Heparin, Low-Molecular-Weight Phase 4
23 HIV Protease Inhibitors Phase 4,Phase 3
24
protease inhibitors Phase 4,Phase 3
25 Serine Proteinase Inhibitors Phase 4
26 Pharmaceutical Solutions Phase 4
27 Protective Agents Phase 4,Phase 3
28 Micronutrients Phase 4,Phase 3,Phase 2
29 Trace Elements Phase 4,Phase 3,Phase 2
30 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
31 Ferrosoferric Oxide Phase 4
32 Hematinics Phase 4,Phase 3
33 Parenteral Nutrition Solutions Phase 4
34 Adjuvants, Immunologic Phase 4
35 Viscosupplements Phase 4
36 Antioxidants Phase 4,Phase 3
37 Phosphodiesterase Inhibitors Phase 4,Phase 3
38 Platelet Aggregation Inhibitors Phase 4,Phase 3
39 Radiation-Protective Agents Phase 4,Phase 3
40 Tocopherols Phase 4,Phase 3
41 Tocotrienols Phase 4,Phase 3
42 Vasodilator Agents Phase 4,Phase 3
43 serine Nutraceutical Phase 4
44 Tocopherol Nutraceutical Phase 4,Phase 3
45 Tocotrienol Nutraceutical Phase 4,Phase 3
46
Gemcitabine Approved Phase 3 95058-81-4 60750
47
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
48
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
49
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
50
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 151)
id Name Status NCT ID Phase
1 Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis Unknown status NCT00265252 Phase 4
2 Vertebral Fracture and Osteonecrosis Associated With High-dose Glucocorticoid Completed NCT00679978 Phase 4
3 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4
4 Comparison of Ceramic-on-Ceramic and Ceramic-on-Highly-Cross-Linked Polyethylene Bearings Completed NCT01806766 Phase 4
5 A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients Completed NCT01345097 Phase 4
6 Ultra-Short Anatomic and Conventional Cementless Stems Cementless Stems in Patients Younger Than Fifty-Five Years Old Completed NCT02338596 Phase 4
7 Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study Completed NCT02139007 Phase 4
8 Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment) Completed NCT00722007 Phase 4
9 Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty Completed NCT02379663 Phase 4
10 Benefit of Orthopedic Navigation in the ARThroplasty of the Hip Completed NCT01496300 Phase 4
11 Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI Recruiting NCT02893293 Phase 4
12 Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis Recruiting NCT02984228 Phase 4
13 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4
14 Management of Mandibular ORN: PENTO as Medical Treatment Active, not recruiting NCT02368457 Phase 4
15 Optetrak Posterior Stabilized Versus Optetrak Hi-Flex Withdrawn NCT00808613 Phase 4
16 Implantation of Bone Marrow Cells to Treat Avascular Necrosis of Femoral Head (ANFH) Unknown status NCT01613612 Phase 2, Phase 3
17 Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial Completed NCT00532220 Phase 3
18 Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head Completed NCT00939900 Phase 3
19 Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial Completed NCT02181101 Phase 3
20 Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease Completed NCT02770625 Phase 3
21 Phase 3 Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head Recruiting NCT01529008 Phase 3
22 Randomized Clinical Trial for the Treatment of Osteonecrosis of the Femoral Head Recruiting NCT01892514 Phase 3
23 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Recruiting NCT02883049 Phase 3
24 Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents Recruiting NCT02684708 Phase 3
25 Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks Recruiting NCT02051218 Phase 3
26 ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee Active, not recruiting NCT01458782 Phase 2, Phase 3
27 Trinity™ BIOLOX Delta™ CoC THR Multi-center Study Active, not recruiting NCT01921309 Phase 3
28 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Active, not recruiting NCT00869206 Phase 3
29 Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ) Not yet recruiting NCT03040778 Phase 3
30 Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis Terminated NCT02114489 Phase 3
31 Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma Terminated NCT02739594 Phase 3
32 A Randomised Multi-centre Study to Compare the Long-term Performance of the Future Hip to 3 Other Implants in Primary Total Hip Replacement Terminated NCT00208468 Phase 3
33 Osteonecrosis of the Hip and Bisphosphonate Treatment Unknown status NCT00781261 Phase 2
34 MBCP Safety and Performance in the Osteonecrosis of Femur Head Unknown status NCT00289575 Phase 2
35 Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip Unknown status NCT02065167 Phase 2
36 Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head Completed NCT00505219 Phase 2
37 PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells Completed NCT01700920 Phase 2
38 Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head Completed NCT02890537 Phase 2
39 Effect of Cycle Ergometer in the Rehabilitation of Elderly Patients With Total Hip Arthroplasty Completed NCT01622465 Phase 2
40 Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents Completed NCT00921557 Phase 2
41 Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Avascular Necrosis of the Femoral Head Completed NCT01643655 Phase 1, Phase 2
42 Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery Completed NCT00393848 Phase 2
43 Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head Recruiting NCT01605383 Phase 1, Phase 2
44 Autologous Bone Marrow Stem Cell Transplantation for Hip Osteonecrosis in Sickle Cell Disease Enrolling by invitation NCT02448121 Phase 1, Phase 2
45 Shock Wave Therapy for Osteoporosis Enrolling by invitation NCT02630381 Phase 2
46 The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells Not yet recruiting NCT03180463 Phase 1, Phase 2
47 Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study Not yet recruiting NCT02632903 Phase 2
48 Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus Terminated NCT00412841 Phase 2
49 Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee Withdrawn NCT00477217 Phase 2
50 Hyper Baric Oxygen Therapy (HBOT) for Spontaneous Osteonecrosis of the Knee Unknown status NCT01950858 Phase 1

Search NIH Clinical Center for Osteonecrosis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Osteonecrosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Osteonecrosis:
JACC
PREOB
Embryonic/Adult Cultured Cells Related to Osteonecrosis:
Cultured cartilage (JACC PMIDs: 16233778 19393556 10738867 16226641 11284883 12043781 16233853 19802670 10679677

Cochrane evidence based reviews: osteonecrosis

Genetic Tests for Osteonecrosis

Anatomical Context for Osteonecrosis

MalaCards organs/tissues related to Osteonecrosis:

39
Bone, Testes, Skin, Endothelial, Bone Marrow, Breast, Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Osteonecrosis:

18
Bone

Publications for Osteonecrosis

Articles related to Osteonecrosis:

(show top 50) (show all 939)
id Title Authors Year
1
An underlying diagnosis of osteonecrosis of bone is associated with worse outcomes than osteoarthritis after total hip arthroplasty. ( 28068972 )
2017
2
The Effectiveness of Free Vascularized Fibular Flaps in Osteonecrosis of the Femoral Head and Neck: A Systematic Review. ( 28092922 )
2017
3
Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. ( 27856150 )
2017
4
Histochemical observation of bony reversal lines in bisphosphonate-related osteonecrosis of the jaw. ( 27989705 )
2017
5
High frequency of osteonecrosis of the jaw among denosumab-treated prostate cancer patients. ( 27921521 )
2017
6
Analysis of different therapeutic protocols for osteonecrosis of the jaw associated with oral and intravenous bisphosphonates. ( 27918742 )
2017
7
Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review. ( 27876532 )
2017
8
The timing of bone SPECT to predict osteonecrosis after internal fixation of femur neck fractures. ( 28089085 )
2017
9
Mycobacterium avium Complex Septic Arthritis Presenting as Osteonecrosis of the Femoral Head in a Patient With Systemic Lupus Erythematosus. ( 28056158 )
2017
10
Multifocal Osteonecrosis in an Adolescent Patient With Systemic Lupus Erythematosus and Ankle Pain. ( 28002155 )
2017
11
Thermal-Induced Osteonecrosis of Adjacent Vertebra after Intradiscal Electrothermal Therapy. ( 28061487 )
2017
12
The starting point for bisphosphonate-related osteonecrosis of the jaw: Alveolar bone or oral mucosa? A randomized, controlled experimental study. ( 27919595 )
2017
13
Genetic polymorphisms of CYP3A4 among Chinese patients with steroid-induced osteonecrosis of the femoral head. ( 27858915 )
2016
14
Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents. ( 27046950 )
2016
15
Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates. ( 27866217 )
2016
16
Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis? ( 27092912 )
2016
17
Comparison of Cemented and Bone Ingrowth Fixation Methods in Hip Resurfacing for Osteonecrosis. ( 27593730 )
2016
18
The efficacy of statins in preventing glucocorticoid-related osteonecrosis in animal models: A meta-analysis. ( 27660333 )
2016
19
Osteonecrosis is unrelated to hip anatomy in children with acute lymphoblastic leukemia. ( 28035753 )
2016
20
Resection and microvascular reconstruction of bisphosphonate-related osteonecrosis of the jaw: The role of microvascular reconstruction. ( 27159622 )
2016
21
Percutaneous Pedicle Screw Fixation with Polymethylmethacrylate Augmentation for the Treatment of Thoracolumbar Intravertebral Pseudoarthrosis Associated with Kummell's Osteonecrosis. ( 27595101 )
2016
22
Medication-related osteonecrosis of the jaw associated with aflibercept. ( 27923511 )
2016
23
Is Assessment of Femoral Head Perfusion During Modified Dunn for Unstable Slipped Capital Femoral Epiphysis an Accurate Indicator of Osteonecrosis? ( 27090261 )
2016
24
Cast-cap splint in the management of medication-related osteonecrosis of the jaw. ( 28017378 )
2016
25
Relative volume measured with magnetic resonance imaging is an articular collapse predictor in hematological pediatric patients with femoral head osteonecrosis. ( 27648169 )
2016
26
Discrepancy between long-term and previously published analysis for osteonecrosis of the jaw under denosumab. ( 27121570 )
2016
27
Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. ( 27956123 )
2016
28
Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws. ( 27591091 )
2016
29
Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. ( 27079903 )
2016
30
Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database. ( 27179251 )
2016
31
Factors influencing progressive collapse of the transposed necrotic lesion after transtrochanteric anterior rotational osteotomy for osteonecrosis of the femoral head. ( 28017874 )
2016
32
Preexisting Periapical Inflammatory Condition Exacerbates Tooth Extraction-induced Bisphosphonate-related Osteonecrosis ofA theA JawA Lesions in Mice. ( 27637460 )
2016
33
Acute Generalized Exanthematous Pustulosis Due to Labetalol; Drug Fever and Leukocytosis Caused by Tigecycline; Toxic Hepatitis Induced by Methylprednisolone Intravenous Pulse Dosing; Mitoxantrone-Related Osteonecrosis of the Jaw; Medications with Anticholinergic Effects and Their Implications in the Elderly. ( 27354743 )
2016
34
Spontaneous Osteonecrosis of the Jaw During Bisphosphonate Therapy: An Unusual Etiology of the Numb Chin Syndrome. ( 27491573 )
2016
35
The importance of early diagnosis in spontaneous osteonecrosis of the knee - A case series with six year follow-up. ( 27198760 )
2016
36
Osteonecrosis of the femoral head associated with pigmented villonodular synovitis. ( 27928593 )
2016
37
Surgical management of osteonecrosis of the humeral head: a systematic review. ( 27198139 )
2016
38
Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ): a systematic review. ( 27025860 )
2016
39
Single-nucleotide polymorphisms of MMP2 in MMP/TIMP pathways associated with the risk of alcohol-induced osteonecrosis of the femoral head in Chinese males: A case-control study. ( 27930516 )
2016
40
OPG and RANKL polymorphisms are associated with alcohol-induced osteonecrosis of the femoral head in the north area of China population in men. ( 27336899 )
2016
41
Extensive Surgical Procedures Result in Better Treatment Outcomes for Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Osteoporosis. ( 28039736 )
2016
42
Bilateral Osteonecrosis of the Femoral Head During Pregnancy Following Two Corticosteroid Injections: A Case Report and Review of the Literature. ( 27182470 )
2016
43
Osteonecrosis as a complication in pediatric patients with acute lymphoblastic leukemia. ( 28009137 )
2016
44
TET3 Mediates Alterations in the Epigenetic Marker 5hmC and Akt Pathway in Steroid-Associated Osteonecrosis. ( 27627619 )
2016
45
Spontaneous osteonecrosis of navicular and talus (SONNT). ( 28018081 )
2016
46
Adjusted protocol for dental extractions in oncology patients taking anti-resorptive drugs may reduce occurrence of medication-related osteonecrosis of the jaw. ( 27012569 )
2016
47
Diseases having an influence on inhibition of angiogenesis as risk factors of osteonecrosis of the jaw. ( 27847735 )
2016
48
Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw. ( 27137436 )
2016
49
Photodynamically dealing with bisphosphonate-related osteonecrosis of the jaw: successful case reports. ( 27585753 )
2016
50
Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I. ( 27501591 )
2016

Variations for Osteonecrosis

Expression for Osteonecrosis

Search GEO for disease gene expression data for Osteonecrosis.

Pathways for Osteonecrosis

GO Terms for Osteonecrosis

Sources for Osteonecrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....